| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-07-2217 |
| P698 | PubMed publication ID | 18566238 |
| P2093 | author name string | Joe G N Garcia | |
| Patrick A Singleton | |||
| Jonathan Moss | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorouracil | Q238512 |
| bevacizumab | Q413299 | ||
| response to drug | Q14599775 | ||
| Protein tyrosine phosphatase receptor type M | Q21108320 | ||
| angiogenesis | Q539568 | ||
| P304 | page(s) | 1669-79 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis | |
| P478 | volume | 7 |
| Q35233407 | Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone |
| Q41644051 | Could Perioperative Opioid Use Increase the Risk of Cancer Progression and Metastases? |
| Q39843460 | Effect of Perioperative Opioids on Cancer Recurrence: A Hypothesis |
| Q33951500 | Increased μ-opioid receptor expression in metastatic lung cancer |
| Q37700635 | MOR1 expression in gastric cancer: a biomarker associated with poor outcome |
| Q37738872 | Methylnaltrexone |
| Q33702325 | Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors |
| Q37308492 | Morphine stimulates platelet-derived growth factor receptor-β signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo |
| Q35151843 | Morphine use in cancer surgery |
| Q37051227 | Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer |
| Q89871060 | Opioids and Cancer Mortality |
| Q57493011 | Perioperative Immunosuppression and Risk of Cancer Progression: The Impact of Opioids on Pain Management |
| Q24317493 | The DEAD box protein Ddx42p modulates the function of ASPP2, a stimulator of apoptosis |
| Q28541351 | The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer |
| Q37308589 | The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia |
| Q38515846 | The mu opioid receptor: A new target for cancer therapy? |
| Q35083162 | The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation |
| Q39442254 | Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer |
| Q37423918 | Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma |
| Q38322817 | Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor. |
| Q34939512 | κ Opioid receptor ligands regulate angiogenesis in development and in tumours |
Search more.